Professor Ian Frazer
Professor

Ian Frazer

Email: 

Background

Professor Ian Frazer is a clinician scientist, trained as a clinical immunologist in Scotland. As a professor at the University of Queensland, he leads a research group working at TRI in Brisbane, Australia on the immunobiology of epithelial cancers. He is recognised as co-inventor of the technology enabling the HPV vaccines, currently used worldwide to help prevent cervical cancer. He heads a biotechnology company, Jingang Medicine (Aus) Pty Ltd, working on new vaccine technologies, and is a board member of several companies and not for profit organisations. He was the inaugural president of the Australian Academy of Health and Medical Sciences, and a member of the Australian National Science and Technology Council. He chairs the Australian Medical Research Advisory Board of the Medical Research Future Fund.

He was recognised as Australian of the Year in 2006. He was recipient of the Prime Ministers Prize for Science, and of the Balzan Prize, in 2008, and was elected Fellow of the Royal Society of London in 2012. He was appointed Companion of the Order of Australia in the Queen’s Birthday Honours list in 2013.

Availability

Professor Ian Frazer is:
Available for supervision
Media expert

Fields of research

Clinical sciences Immunology Oncology and carcinogenesis

Qualifications

  • Bachelor (Honours) of Science (Advanced), University of Edinburgh
  • Bachelor of Medicine Surgery, University of Edinburgh
  • Doctoral Diploma of Medicine, University of Melbourne
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
  • Royal College of Physicians of Edinburgh, Royal College of Physicians of Edinburgh

Search Professor Ian Frazer’s works on UQ eSpace

461 works between 1977 and 2025
All (461) Journal Article (387) Book Chapter (14) Conference Publication (55) Book (1) Other Outputs (3) Edited Outputs (1)

1 - 20 of 461 works

2025

Journal Article

Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine

Quang, Chau, Anderson, Jeremy, Russell, Fiona M., Reyburn, Rita, Ratu, Tupou, Tuivaga, Evelyn, Devi, Rachel, Frazer, Ian H., Garland, Suzanne M., Wines, Bruce, Hogarth, P. Mark, Mulholland, Kim, Chung, Amy W., Toh, Zheng Quan and Licciardi, Paul V. (2025). Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine. Nature Communications, 16 (1) 2130. doi: 10.1038/s41467-025-57443-z

Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine

2025

Journal Article

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade

Li, Junjie, Luo, Yuandong, Fu, Quanlan, Tang, Shuxian, Zhang, Pingping, Frazer, Ian H., Liu, Xiaosong, Wang, Tianfang and Ni, Guoying (2025). Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade. Scientific Reports, 15 (1) 3789. doi: 10.1038/s41598-025-87687-0

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade

2024

Journal Article

STING nanoagonist boosts antitumor immunity of therapeutic DNA vaccines

Jia, Wencong, Chandra, Janin, Teoh, Siok Min, Tolley, Lynn, Yang, Haotian, Tse, Brian W. C., Sokolowski, Kamil A., Liang, Xiaowen, Crawford, Darrell H. G., Steel, Jason C., Yu, Chengzhong, Roberts, Michael S., Frazer, Ian H., Chen, Yu, Wang, Haolu and Yu, Meihua (2024). STING nanoagonist boosts antitumor immunity of therapeutic DNA vaccines. Nano Letters, 24 (49), 1-10. doi: 10.1021/acs.nanolett.4c03846

STING nanoagonist boosts antitumor immunity of therapeutic DNA vaccines

2024

Journal Article

Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survival

Dang, Thi Viet Trinh, Gillinder, Kevin R., Nguyen, Quan, Mulay, Onkar, Vo, Tuan, Mehdi, Ahmed M., Zhou, Chenhao, Brooks, Andrew J., Leggatt, Graham R., Hume, David A., Frazer, Ian H. and Chandra, Janin (2024). Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survival. Clinical and Translational Immunology, 13 (12) e70018, 1-18. doi: 10.1002/cti2.70018

Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survival

2024

Conference Publication

Epithelial cancers demonstrate IL34-associated dysfunction of Langerhans cells

Dang, Thi Viet Trinh, Gillinder, Kevin R., Nguyen, Quan, Mulay, Onkar, Vo, Tuan, Mehdi, Ahmed M., Zhou, Chenhao, Brooks, Andrew J., Asplett, Kiran, Leggatt, Graham R., Hume, David A., Frazer, Ian H. and Chandra, Janin (2024). Epithelial cancers demonstrate IL34-associated dysfunction of Langerhans cells. AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy, Boston, MA, United States, 18-21 October 2024. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/2326-6074.tumimm24-a001

Epithelial cancers demonstrate IL34-associated dysfunction of Langerhans cells

2024

Journal Article

A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma

Ladwa, Rahul, Chandra, Janin, Woo, Wai-Ping, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Xu, Yan, Panizza, Benedict, Frazer, Ian and Porceddu, Sandro V. (2024). A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Frontiers in Oncology, 14 1419258, 1-8. doi: 10.3389/fonc.2024.1419258

A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma

2024

Conference Publication

A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate

Ladwa, Rahul, Lee, Jenny H.J., Porceddu, Sandro V., McGrath, Margaret Louise, Cooper, Caroline, Liu, Howard, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle K., Clark, Jonathan, Le, Dieu, Pauley, Marketa, Gonzalez-Cruz, Jazmina, Frazer, Ian, Hughes, Brett Gordon Maxwell and Panizza, Benedict J. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.9514

A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate

2024

Journal Article

Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs

Bromfield, Jacoba I., Zaugg, Julian, Straw, Rodney C., Cathie, Julia, Krueger, Annika, Sinha, Debottam, Chandra, Janin, Hugenholtz, Philip and Frazer, Ian H. (2024). Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs. mSphere, 9 (4) e0055523, e0055523. doi: 10.1128/msphere.00555-23

Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs

2024

Journal Article

Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity

Wright, Quentin G., Sinha, Debottam, Wells, James W., Frazer, Ian H., Gonzalez Cruz, Jazmina L. and Leggatt, Graham Robert (2024). Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity. Journal for ImmunoTherapy of Cancer, 12 (1) e007960. doi: 10.1136/jitc-2023-007960

Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity

2023

Journal Article

Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure

Causer, Andrew, Tan, Xiao, Lu, Xuehan, Moseley, Philip, Teoh, Siok M., Molotkov, Natalie, McGrath, Margaret, Kim, Taehyun, Simpson, Peter T, Perry, Christopher, Frazer, Ian H., Panizza, Benedict, Ladwa, Rahul, Nguyen, Quan and Gonzalez-Cruz, Jazmina L. (2023). Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure. n p j Precision Oncology, 7 (1) 89, 89. doi: 10.1038/s41698-023-00444-2

Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure

2023

Journal Article

Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts

Veitch, Margaret, Beaumont, Kimberly, Pouwer, Rebecca, Chew, Hui Yi, Frazer, Ian H., Soyer, H. Peter, Campbell, Scott, Dymock, Brian W., Harvey, Andrew, Cock, Terrie-Anne and Wells, James W. (2023). Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts. Journal for ImmunoTherapy of Cancer, 11 (9) e006783, 1-15. doi: 10.1136/jitc-2023-006783

Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts

2023

Journal Article

Skin-grafting and dendritic cell “boosted” humanized mouse models allow the pre-clinical evaluation of therapeutic cancer vaccines

Zeng, Bijun, Moi, Davide, Molotkov, Natalie, Tolley, Lynn, Frazer, Ian Hector, Perry, Christopher, Dolcetti, Riccardo, Mazzieri, Roberta and Cruz, Jazmina L. G. (2023). Skin-grafting and dendritic cell “boosted” humanized mouse models allow the pre-clinical evaluation of therapeutic cancer vaccines. Cells, 12 (16) 2094, 1-21. doi: 10.3390/cells12162094

Skin-grafting and dendritic cell “boosted” humanized mouse models allow the pre-clinical evaluation of therapeutic cancer vaccines

2023

Journal Article

Salivary micro RNAs as biomarkers for oropharyngeal cancer

Ekanayake Weeramange, Chameera, Tang, Kai Dun, Barrero, Roberto A., Hartel, Gunter, Liu, Zhen, Ladwa, Rahul, Langton-Lockton, Julian, Frazer, Ian, Kenny, Lizbeth, Vasani, Sarju and Punyadeera, Chamindie (2023). Salivary micro RNAs as biomarkers for oropharyngeal cancer. Cancer Medicine, 12 (14), 15128-15140. doi: 10.1002/cam4.6185

Salivary micro RNAs as biomarkers for oropharyngeal cancer

2023

Journal Article

Targeting Staphylococcus aureus dominated skin dysbiosis in actinic keratosis to prevent the onset of cutaneous squamous cell carcinoma: Outlook for future therapies?

Bromfield, Jacoba Isobella, Hugenholtz, Philip, Frazer, Ian Hector, Khosrotehrani, Kiarash and Chandra, Janin (2023). Targeting Staphylococcus aureus dominated skin dysbiosis in actinic keratosis to prevent the onset of cutaneous squamous cell carcinoma: Outlook for future therapies?. Frontiers in Oncology, 13 1091379, 1091379. doi: 10.3389/fonc.2023.1091379

Targeting Staphylococcus aureus dominated skin dysbiosis in actinic keratosis to prevent the onset of cutaneous squamous cell carcinoma: Outlook for future therapies?

2022

Journal Article

HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer

Mehdi, Ahmed M., Zhou, Chenhao, Turrell, Gavin, Walpole, Euan, Porceddu, Sandro, Frazer, Ian H. and Chandra, Janin (2022). HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer. Cancer Gene Therapy, 30 (4), 1-12. doi: 10.1038/s41417-022-00577-9

HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer

2022

Journal Article

Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade

Sinha, Debottam, Moseley, Philip, Lu, Xuehan, Wright, Quentin, Gabrielli, Brian, Frazer, Ian H. and Cruz, Jazmina L. G. (2022). Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade. Cancers, 14 (24) 6150, 1-26. doi: 10.3390/cancers14246150

Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade

2022

Journal Article

Environmental pathways affecting gene expression (E.PAGE) as an R package to predict gene–environment associations

Muralidharan, Sachin, Ali, Sarah, Yang, Lilin, Badshah, Joshua, Zahir, Syeda Farah, Ali, Rubbiya A., Chandra, Janin, Frazer, Ian H., Thomas, Ranjeny and Mehdi, Ahmed M. (2022). Environmental pathways affecting gene expression (E.PAGE) as an R package to predict gene–environment associations. Scientific Reports, 12 (1) 18710, 1-19. doi: 10.1038/s41598-022-21988-6

Environmental pathways affecting gene expression (E.PAGE) as an R package to predict gene–environment associations

2022

Conference Publication

Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo

Wright, Q., Sinha, D., Gonzalez-Cruz, J., Frazer, I. and Leggatt, G. (2022). Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo. ESMO Immuno-Oncology Congress 2022, Geneva, Switzerland, 7-9 December 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.iotech.2022.100289

Targeting of immune regulatory proteins through locoregional delivery of mAbs augments CD8 T cell mediated anti-tumour responses in vivo

2022

Conference Publication

Gene-therapy based modulation of antigen-presenting cells within hyperproliferative epithelium to restore immunity

Dang, T. V. T., Gillinder, K. G., Brooks, A. J., Asplett, K., Tolley, L. K., Hume, D. A., Leggatt, G. R., Frazer, I. H. and Chandra, J. (2022). Gene-therapy based modulation of antigen-presenting cells within hyperproliferative epithelium to restore immunity. 29th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy (ESCGT), Edinburgh, United Kingdom, 11-14 October 2022. New Rochelle, NY United States: Mary Ann Liebert.

Gene-therapy based modulation of antigen-presenting cells within hyperproliferative epithelium to restore immunity

2022

Journal Article

Caerin 1.1/1.9 enhances antitumour immunity by activating the IFN-α response signalling pathway of tumour macrophages

Yang, Xiaodan, Liu, Xiaosong, Li, Junjie, Zhang, Pingping, Li, Hejie, Chen, Guoqiang, Zhang, Wei, Wang, Tianfang, Frazer, Ian and Ni, Guoying (2022). Caerin 1.1/1.9 enhances antitumour immunity by activating the IFN-α response signalling pathway of tumour macrophages. Cancers, 14 (23) 5785, 1-22. doi: 10.3390/cancers14235785

Caerin 1.1/1.9 enhances antitumour immunity by activating the IFN-α response signalling pathway of tumour macrophages

Current funding

  • 2022 - 2025
    A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma with the use of neoadjuvant Pembrolizumab - DESQUAMATE
    Metro South Hospital and Health Service
    Open grant
  • 2022 - 2025
    Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer (NHMRC Ideas Grant administered by Griffith University).
    Griffith University
    Open grant
  • 2020 - 2025
    Pathogen promoters of squamous epithelial cancer
    NHMRC Investigator Grants
    Open grant

Past funding

  • 2022 - 2024
    Elucidating early carcinogenic mechanisms dysregulating Langerhans cell differentiation during experimental oral squamous cell carcinoma (ZCAI Grant led by The Hebrew University of Jerusalem)
    The Hebrew University of Jerusalem
    Open grant
  • 2021 - 2023
    Assessment of predictors of response to checkpoint blockade
    PA Research Foundation
    Open grant
  • 2021 - 2023
    Preclinical development of Q2361, a transforming new drug for skin cancer prevention in organ transplant recipients
    NHMRC Development Grant
    Open grant
  • 2021 - 2023
    Tissue microarray analysis of oropharyngeal squamous cell carcinoma tumour specimens using markers of genomic instability and proteomics (PARF Grant led by MSHHS)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2022
    Saving your skin: physiology of immune regulation in mammalian lymph nodes
    ARC Discovery Projects
    Open grant
  • 2018 - 2020
    Generation of a preclinical humanized mouse model to evaluate the efficacy of experimental therapies against cervical cancer
    Australian Society for Colposcopy & Cervical Pathology Incorporated
    Open grant
  • 2018 - 2019
    Human HPV Assay Development and Testing
    Admedus Vaccines Pty Ltd
    Open grant
  • 2017 - 2024
    ARC Training Centre for Innovation in Biomedical Imaging Technology
    ARC Industrial Transformation Training Centres
    Open grant
  • 2017 - 2018
    Is there really a viral cause for skin cancer?
    Australasian College of Dermatologists Scientific Research Fund
    Open grant
  • 2017
    Reducing adverse reactions and boosting immune response to HPV vaccination with exercise
    University of Sydney
    Open grant
  • 2017 - 2018
    Memory CD8+ T-cell function in squamous cell carcinoma
    Cancer Council Queensland
    Open grant
  • 2017 - 2019
    Targeting immunomodulatory molecules on T cells in non-melanoma skin cancer
    Cancer Council Queensland
    Open grant
  • 2016 - 2019
    Rapid functional and taxonomic skin microbe characterisation
    ARC Linkage Projects
    Open grant
  • 2016
    Establishing a gnotobiotic germ-free mouse facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    The Australian human microbiota project-microbe isolation facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2016
    To assess the effect of treatment with the experimental peptide Alloferon on the immune response of C57 mice to K14E7 skin grafts
    Data Management Med-High-Tech GmbH
    Open grant
  • 2015 - 2016
    Evaluate ODS MOA in inhibiting DNCB-induced ear swelling in K14-E7.
    UniQuest Pty Ltd
    Open grant
  • 2015 - 2016
    The Vevo 2100 micro-ultrasound plus LAZR photoacoustic imaging platform (ARC LIEF project administered by Queensland University of Technology)
    Queensland University of Technology
    Open grant
  • 2015 - 2017
    Deciphering novel control mechanisms in the skin
    ARC Discovery Projects
    Open grant
  • 2015 - 2019
    Immunological therapies for cancer, chronic infection and autoimmunity
    NHMRC Program Grant
    Open grant
  • 2014 - 2017
    Viral Oncogenesis in Oral Squamous Cell Carcinoma (Garnett Passe and Rodney Williams Memorial Foundation Conjoint Grant)
    Garnett Passe/Rodney Williams Memorial Foundation
    Open grant
  • 2014 - 2015
    Chemokine involvement in the differential response of Actinic Keratosis and Squamous Cell Carcinoma to Imiquimod therapy
    Cancer Council Queensland
    Open grant
  • 2014 - 2018
    Determinants of progression of actinic keratoses to squamous cancer
    NHMRC Project Grant
    Open grant
  • 2013 - 2016
    Investigating a novel, physical adjuvant for improving immune responses of vaccines
    ARC Linkage Projects
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2013 - 2015
    Optimising immunotherapy for squamous cancer
    Cancer Research Institute (USA)
    Open grant
  • 2013 - 2016
    Sterile inflammation as a determinant of adaptive immunity
    ARC Discovery Projects
    Open grant
  • 2013 - 2014
    Infection and immunity in squamous skin cancer
    Bupa Foundation (Australia) Ltd
    Open grant
  • 2013 - 2015
    Optimizing a vaccine for HPV immunotherapy
    NHMRC Development Grant
    Open grant
  • 2012 - 2018
    Queensland Centre of Excellence for Head and Neck Cancer
    Metro South Hospital and Health Service
    Open grant
  • 2012 - 2015
    Development of dense gas technology platforms for the formulation of oral vaccines (ARC Linkage Project administered by the University of New South Wales)
    University of New South Wales
    Open grant
  • 2012 - 2013
    RNA interference and the Immune System (NHMRC Project Grant administered by Griffith University)
    Griffith University
    Open grant
  • 2012 - 2013
    Hunting for viruses that cause skin cancer
    PA Research Foundation Private Practice Trust Fund Research Support Grants
    Open grant
  • 2012
    Automated electrophoretic bioanalysis
    NHMRC Equipment Grant
    Open grant
  • 2011 - 2012
    Comprehensive cell imaging facility (ARC LIEF Grant administered by QUT)
    ARC LIEF Collaborating/Partner Organisation Contributions
    Open grant
  • 2011 - 2012
    Investigating the mechanisms by which immune cells (particularly T cells and NKT cells) target and eliminate cells expressing tumour antigens
    Cancer Council Queensland
    Open grant
  • 2011
    Laser Scanner for Biomolecular Imaging
    NHMRC Equipment Grant
    Open grant
  • 2010
    A sustainable program for prevention of Cervical Cancer in Vanuatu
    International Agency for Research on Cancer
    Open grant
  • 2010
    Automated flow cytometry
    UQ Major Equipment and Infrastructure
    Open grant
  • 2010 - 2014
    Immunological therapies for cancer, chronic infection and autoimmunity
    NHMRC Program Grant
    Open grant
  • 2010 - 2012
    Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch
    ARC Discovery Projects
    Open grant
  • 2010
    PET/CT (positron emission tomography - computed tomography)
    UQ Major Equipment and Infrastructure
    Open grant
  • 2010 - 2011
    PET/CT (positron emission tomography - computed tomography)
    Research Donation Generic
    Open grant
  • 2010 - 2011
    PET/CT (positron emission tomography - computed tomography)
    Research Donation Generic
    Open grant
  • 2010 - 2012
    RNA interference and the Immune System
    NHMRC Project Grant
    Open grant
  • 2009 - 2011
    Proteomics sample preparation workstation for the UQ Diamantina Institute and future Translational Research Institute
    Ramaciotti Foundation
    Open grant
  • 2009 - 2011
    Nanopatch immunisation against pandemic Novel A (H1N1) influenza virus 09: potent immunity at a reduced dose
    NHMRC Urgent Research - H1N1 Influenza 09
    Open grant
  • 2009 - 2014
    Novel Interventions Against HPV-associated Neoplasia
    University of Wisconsin-Madison
    Open grant
  • 2009 - 2012
    International Needle-free Vaccination Alliance (INVax)
    Queensland Government Smart State National and International Research Alliances Program
    Open grant
  • 2009 - 2010
    Multiphoton microscopy of living animals as a tool for immunology and cell biology studies
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2009 - 2011
    Nanopatch immunisation against pandemic influenza: improved immune responses at a reduced dose.
    NHMRC Project Grant
    Open grant
  • 2009 - 2010
    RNA interference and Immunity
    Cancer Council Queensland
    Open grant
  • 2009 - 2011
    The immunogenetics of ankylosing spondylitis: a genetic and functional investigation of IL23R and related genes
    NHMRC Project Grant
    Open grant
  • 2008 - 2015
    A comprehensive genomics facility for the UQ Diamantina Institute for Cancer, Immunology and Metabolic Medicine
    Australian Cancer Research Foundation
    Open grant
  • 2007
    Genetic and Genomic Analysis Research Facility
    RL Cooper Medical Research Foundation Limited
    Open grant
  • 2007 - 2009
    MPM non-invasive imaging of biological interactions following drug delivery with micro-nanoprojection patches
    NHMRC Project Grant
    Open grant
  • 2007 - 2009
    Non-viral vectors for targeted delivery of RNAi nucleotides to cervical cancers
    NHMRC Project Grant
    Open grant
  • 2006 - 2007
    Improving Immunotherapy by Inhibiting IL 10 Mediated Immune Deviation
    NHMRC Development Grant
    Open grant
  • 2006 - 2008
    Mechanisms of dendritic cell-induced T-cell tolerance
    NHMRC Project Grant
    Open grant
  • 2006 - 2007
    Molecular mechanisms of regulatory expression of human papillomavirus L1 genes in keratinocytes
    Queensland Cancer Fund
    Open grant
  • 2005 - 2007
    A phase IB trial of virus like particle immunotherapy for HPV associated infection
    Cancer Research Institute (USA)
    Open grant
  • 2005
    Cationic Complexes for Targeted Delivery of Polynucleotide Vaccines to Skin Cells
    University of Queensland Research Development Grants Scheme
    Open grant
  • 2005 - 2009
    Immunological therapies for cancer and autoimmunity
    NHMRC Program Grant
    Open grant
  • 2005 - 2007
    Jet break-up of emulsions for the production of designer micro particulate drug delivery systems - Administering Institution JCU
    James Cook University
    Open grant
  • 2005
    NHMRC Equipment Grant : Estimation of drugs, peptides and metabolites using HPLC-Mass-spectrometry-microdialysis
    NHMRC Equipment Grant
    Open grant
  • 2005
    NHMRC_Equipment Grant =Techniplast Caging System and Mobile laminar flow cabinets, air-conditioning upgrade
    NHMRC Equipment Grant
    Open grant
  • 2005 - 2006
    Optimising Immunotherapy in Tumour Antigen Experienced Host
    Queensland Cancer Fund
    Open grant
  • 2005 - 2006
    The role of NKT and CD8 cells in tumour immunotherapy using epithelial tumour models
    Queensland Cancer Fund
    Open grant
  • 2004 - 2005
    NHMRC_Equipment Grant _HLTH_CICR_Med SCD
    NHMRC Equipment Grant
    Open grant
  • 2003 - 2010
    Study Of HPV 6L1 Virus Like Particles As Therapeutic Vaccine For Genital Warts And Recurrent Respiratory Papillomatosis
    Wellcome Trust
    Open grant
  • 2003 - 2004
    PAHF block funding
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2003
    Array WoRx-e Microarray-Scanner System
    NHMRC Equipment Grant
    Open grant
  • 2003 - 2004
    Evaluating Therapeutic Interventions to Overcome Tolerance to Tumour Antigen
    Queensland Cancer Fund
    Open grant
  • 2003 - 2004
    Immunoregulatory Immune Responses To A Peripherally Presented Tumour Antigen
    NHMRC Project Grant
    Open grant
  • 2002
    A skin graft model of immunotherapy for cervical cancer.
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2002 - 2004
    Effective immunotherapy for HPV associated cervical cancer precusor lesions
    NHMRC Project Grant
    Open grant
  • 2002 - 2003
    How does tRNA correlate with codon usage to regulate the expression of papillomavirus late genes?
    Queensland Cancer Fund
    Open grant
  • 2001 - 2004
    Codon usage/tRNA matching: a novel method of gene regulation in plants
    Grains Research & Development Corporation
    Open grant
  • 2001 - 2002
    A Phase 1B Trial of Specific Immunotherapy for Recurrent Respiratory Papillomatosis
    NHMRC Project Grant
    Open grant
  • 2001
    Can Response To The Antiviral Drug Lmiquimod Be Predicted By Pretreatment Genetic Testing? A Phase 4 Clinical Trial
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2001 - 2003
    CTL Avidity as a Determinant of the Mature, Antigen-specific Immune Repertoire
    NHMRC Project Grant
    Open grant
  • 2001
    Endogenous Antigen Presentation By Epithelial Tumours
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2000
    A model for epithelial tumour immunotherapy
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2000
    Identification of papilolomavirus epitopes recognised in man, and development of human anti-HPV monoclonal antibodies
    Cancer Bequest Fund
    Open grant
  • 1999 - 2001
    Development and evaluation of hybrid novel mucosal vaccines
    United States National Institutes of Health
    Open grant
  • 1999 - 2002
    Genotype specific and genotype cross reactive cell mediated immunity to VLP based papillomavirus vaccines
    Cancer Research Institute (USA)
    Open grant
  • 1999 - 2000
    A phase II clinical trial in patients with metastatic melanoma comparing autologous dendritic cells pulsed with autologous tumour peptides and melanoma associated peptides linked to the endoplasmic re
    Queensland Cancer Fund
    Open grant
  • 1999
    Cell mediated immunity in the early control of papillomavirus infection
    Mayne Bequest Fund
    Open grant
  • 1999 - 2001
    Cell mediated immunity in the early control of papillomavirus infection
    NHMRC Project Grant
    Open grant
  • 1999
    CTL avidity and cell number as determinants of E7 tumour regression in vivo
    Cancer Bequest Fund
    Open grant
  • 1999 - 2001
    Determinants of Effective Immunotherapy for Epithelial Tumours
    NHMRC Project Grant
    Open grant
  • 1999 - 2000
    Genotype specific and genotype cross reactive cell mediated immunity to VLP based Papillomavirus vaccines
    Queensland Cancer Fund
    Open grant
  • 1999
    Genotype specific and genotype cross reactive cell mediated immunity to VLP based papillomavirus vaccines
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1999 - 2001
    How does papillomavirus regulate its late gene expression
    NHMRC Project Grant
    Open grant
  • 1999 - 2001
    The Role of the Human Papillomavirus in Alpha-6-Integrin Activation and Cell Growth
    NHMRC Project Grant
    Open grant
  • 1998
    A Phase I/II Clinical Trial to Test Tumour Vaccines Comprising with Protein or Autologous Tumour Antigen Autologous Dandritic Cells Generated in a Closed Bag System Pulsed
    Mayne Bequest Fund
    Open grant
  • 1998
    The Role of CTL Avidity and Cytokine Environment in the Control of Papillomavirus Infection and Epithelial Tumours
    Mayne Bequest Fund
    Open grant
  • 1998
    The role of E2F in skin cancer development
    Queensland Cancer Fund
    Open grant
  • 1997
    Immune evasion in cervical cancer through block detection of MHC locus genes
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1997 - 1999
    Polyprotein immunogens as a novel approach to viral vaccines
    ARC Collaborative Grant (SPIRT)
    Open grant
  • 1997
    Polyprotein immunogens as a novel approach to viral vaccines
    Commonwealth Serum Laboratories
    Open grant
  • 1997
    Presentation of antigen by kearatinocytes to naive and memory T helper cells
    Mayne Bequest Fund
    Open grant
  • 1997 - 1999
    T help as a determinant of effector CTL function in immunotherapy
    NHMRC Project Grant
    Open grant
  • 1997
    The role of E2F1 in human skin cancer development
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1996 - 1997
    Clinical drug trial
    3M Australia Pty Limited
    Open grant
  • 1996 - 1997
    International papillomavirus workshop
    United States National Institutes of Health
    Open grant
  • 1996 - 1997
    Micromanipulator equipment
    Viertel Foundation (Sylvia and Charles Viertel)
    Open grant
  • 1996 - 1998
    Binding and uptake of papillomavirus particles and epithelial cells
    NHMRC Project Grant
    Open grant
  • 1996 - 1997
    Collaborations between the Centre for Immunology and Cancer Research and the McArdle Institute for Cancer Research
    Quality Funds Round 3
    Open grant
  • 1996
    How do viruses evade the interferon system
    UQ Foundation
    Open grant
  • 1996
    Immune evasion in cervical cancer through block deletions of MHC locus genes
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1996 - 1998
    Immune requirements for killing epithelial tumour cells
    Queensland Cancer Fund
    Open grant
  • 1995 - 1998
    The immunobiology of HPV-associated cancers
    United States National Institutes of Health
    Open grant
  • 1995
    Optimising immunity towards tumours by vaccination
    Cancer Bequest Fund
    Open grant
  • 1995
    Testing immunotherapy for cancer using an automated counting system
    Ramaciotti Foundation
    Open grant

Availability

Professor Ian Frazer is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Professor Ian Frazer directly for media enquiries about:

  • Allergy
  • Autoimmune disease
  • Cancer - immunity
  • Cancer - vaccines to prevent
  • Cervical cancer vaccine
  • Education - medical
  • Genital wart virus disease
  • Host-virus interactions
  • Immunity
  • Immunodeficiency
  • Immunology
  • Medical education
  • Papillomavirus vaccines
  • Pathology
  • Transplantation immunology
  • Tumour immunology
  • Tumour vaccines
  • Vaccines
  • Viral infection
  • Viral vaccines
  • Viruses
  • Warts - genital

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au